A First in human of ZP10068

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2024 According to a Zealand Pharma media release, Alexion has discontinued development of ZP10068 citing business reasons and plans to return the pre-clinical asset to Zealand.
04 Mar 2024 New trial record
27 Feb 2024 According to a Zealand Pharma media release, company has completed pre-clinical and CMC activities for the ZP10068. Subsequent regulatory, clinical and development efforts will be led and conducted by Alexion. Company expects to initiate first-in-human trial in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com